Disclaimers

DISCLAIMER: This site's contents are for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this Site!

If you think you may have a medical emergency, call your doctor or 911 immediately. The Site may contain health- or medical-related materials that are sexually explicit. If you find these materials offensive, please do not come to this Site. This site cannot guarantee the complete accuracy of these information-please check with your health providers. Reliance on any information provided by this Site is solely at your own risk.

Saturday, September 22, 2012

Patients with BRCA mutation and ovarian cancer prognosis

Approximately 10% of women with invasive epithelial ovarian cancer carry deleterious gene mutations in BRCA1 or BRCA2. A study in Journal American Medical Association suggested that BRCA2-related ovarian cancer seemed to have an improved prognosis, but the effect of BRCA1 remains unclear. The five-year all-cause mortality rate for noncarriers was 47 percent compared with 45 percent for BRCA1 mutation carriers and 36 percent for BRCA2 mutation carriers.


Reference:

Bolton KL, et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.  JAMA. 2012;307(4):382
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)